Traxion Sab De Cv Ord Shs GRPOF

RE:RE:RE:RE:RE:financial risk at TBP MD RECENT RELEASE

[kmoneymoney]

@DONOOW - Well, the submission of Reduvo to Health Canada was accepted on or around June 2nd. Health Canada doesn't typically accept submissions to start with if they see any red flags, and considering that this drug has existed for 20+ years in the U.S. as dronabinaol - for which most of the TBP's application data is based off of there is no real forseeable reason this drug could be rejected. Also, it's been almost two months since application submission and TBP has not had one comment from the regulators - if they did they woul dhave to announce their response to the market. 

Guy has also been pretty consistant in his approxiamte Q3 target for the officialy hearing back from Health Canada and recieving the DIN - and I'm sure he's got a good idea of how long this sortof thing takes. But let' say he doesn't an he's off by three months (one quarter) - we are still going to get approval by the end of the year which turns this company from a drug developer into a commercialized drug producer with INCOME. While this drug only addresses an $80 million chemo treatment market in Canada, this is a massive validation of their abilities as a cpmpany to tick all the boxes and officially bring a drug to market, it will also lay the groundwork for QUIXLEEF; additionaklly the off-label Reduvo perscriptions could be massive as now physicians can perscribe a cannabinoid drug, even though it's meant for chemo, people could perscirbed it for pain, inflamation, etc.